Login / Register
Discussion Forums
Search
  /Go
Advanced Search
   Listen Live
Click for a list of RSS feeds
Media clips require Real Player
South African Broadcasting Corporation Copyright ©
2000 - 2005 SABC
 

Tests of new Aids gel show promise for women

February 25, 2008, 11:30

Researchers have today reported that a gel that uses a popular HIV drug to protect women from the Aids virus is safe and acceptable to women, although it is too early to know if it actually prevents infection.

The gel uses the drug tenofovir and is sold under the name Viread by Gilead Sciences Inc.

The study released at a meeting of Aids researchers in India is a welcome piece of good news for the struggling field of microbicides. It involved 200 sexually active HIV negative women in the US and India.

"The gel is safe to use, and well tolerated by HIV negative women. That's a key message in our findings," said Doctor Craig Hoesley of the University of Alabama at Birmingham. "This sets the stage for larger studies to see if tenofovir can prevent HIV infection."

Microbicides are products such as gels or creams that can be applied on the vagina or anus to prevent transmission of the HIV that causes Aids.

Just last week a study showed one candidate called Carraguard did not protect women from infection. Two other potential microbicides have made women more likely to become infected, a spermicidal called nonoxynol-9 and a product called Ushercell, made by Toronto, Canada-based polydex pharmaceuticals.

Tenofovir has potential
The tenofovir product appears to be safe, said the research team funded by the National Institutes of Health. It is the first potential microbicide to use a licensed Aids drug. It was a phase II clinical trial that is designed to show safety, not that it was effective.

"It is a critical time for all of us engaged in HIV prevention and I truly believe we are turning a corner," said Sharon Hillier of the University of Pittsburgh School of Medicine, who led the study.

According to the United Nations Agency, UNAids, women make up 46% of the 33.2 million people infected with the Aids virus.

Hillier said it is not clear how long tenofovir stays in a woman's vagina. "Currently, there are very encouraging studies suggesting that even when tenofovir is gone from the vagina the drug itself is there in the vaginal tissue."

"The important thing we learned is that covert use or secret use, is not an important parameter for women, and that in fact we found that 12% of the women who used the gel said it made sex more pleasurable and none of the women said that the gel made sex less pleasurable."

Eighty-percent of the women told to use the gel within two hours of having sex said they had done so. "We asked women 'How acceptable is this as a prevention option, is it too messy, is it a nuisance, and will you use it?' Our study showed they will use it and they're not bothered by the gel," Hoesley said. – Reuters

Click here to send this article to a friend     Click here for a printable version of this article    
RELATED STORIES
Rethink on Aids after trial fails: expert (February 19, 2008, 11:15)
Microbicide conference under way (May 23, 2007, 09:45)
SA to spend more on Aids (February 20, 2008, 15:15)
 
 Weather
Min: 3
Max: 18
Current Affairs
 Fokus
 Special Assignment
 Cutting Edge
Other Site Features
 SABC News International
 News Agency
 Afrique Nouvelles
 Audio Bulletins
 Video Bulletins
 Personalise
 News Awards
 Community Media Awards
 Discussion Forums
 Matric results info
 FAQs
 Contact Us
 Help
 Disclaimer
Sponsored Links
Online insurance
Life insurance
Life Insurance for Women
Insurance for Women
New & used cars
Compare Insurance Quotes
Gold Credit Card